Alexion Pharmaceuticals, Inc. (ALXN) is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.
Alexion Announces Phase 3 Trial Failure; Shares Down 9% In After-Hours Trade Shares of Alexion Pharmaceuticals (ALXN) are down 9% in after-hours trade after the company announced that it had failed a phase 3 trial. The phase 3 trial, known as the REGAIN study, was testing the company's drug Soliris in patients with refractory generalized myasthenia gravis (refractory gMG.) Read full article here: http://www.talkmarkets.com/content/...shares-down-9-in-after-hours-trade?post=96535
Weekly chart: MACD as low as it'll go. Price fell through the bottom of the channel but momentum didn't fall as far. Purple moving average shown is the 20-week (currently +10% from price).
Keeping an eye on this one. I guess currently in biotech-land there's something called the ASH conference.
Alexion Pharmaceuticals says CEO, CFO resigns Dec 12 Alexion Pharmaceuticals Inc said on Monday that Chief Executive David Hallal had resigned, effective immediately, and named board member David Brennan as interim CEO. The company also said Chief Financial Officer Vikas Sinha left to pursue other opportunities, effective immediately, and would be succeeded by David Anderson, who was earlier CFO at Honeywell International Inc. http://in.reuters.com/article/alexion-pharms-moves-ceo-idINL4N1E73G8
Drug company Alexion Pharmaceuticals (ALXN) is also likely to move higher after reaffirming its full-year earnings and sales guidance.
Been in a range for 2 years with a nice spring, just started peeking through declining tops line. Think this one is ready to move.